Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions

Medical Care

Volumn 42, Issue 2, 2004, Pages 164-175

  Weinfurt, Kevin P ^c   Castel, Liana D ^c   Li, Yun ^a,c   Timbie, Justin W ^b,c   Glendenning, G Alastair ^d   Schulman, Kevin A ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HARVARD UNIVERSITY   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonates; Breast cancer; Growth curve modeling; Quality of life

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE TUMOR; BREAST TUMOR; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

BONE NEOPLASMS; BREAST NEOPLASMS; CANADA; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; QUALITY OF LIFE; UNITED STATES;

EID: 1442279409     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000108746.69256.45     Document Type: Article

References (29)

1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718-1729.
2. Donaldson GW, Moinpour CM. Individual differences in quality-of-life treatment response. Med Care. 2002;40:III39-III53.
3. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743-753.
4. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138.
5. Ganz PA, Lee JJ, Sim MS, et al. Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. J Clin Epidemiol. 1992;45:473-485.
6. Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with long-standing vertebral ostcoporotic fracture. Ostaoporos Int. 1999:9:508-515.
7. Janjan NA, Payne R, Gillis T, et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage. 1998;16:171-178.
8. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996:334:488-493.
9. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
10. Hortobagyi ON, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785-1791.
11. Hortobagyi ON, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16: 2038-2044.
12. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88: 1082-1090.
13. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate. reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17:846-854.
14. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
15. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
16. Rosen L, Gordon DH, Dugan W, et al. Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion. Presented as a poster at the 27th Congress of the European Society for Medical Oncology; Nice, France; October 18-22, 2002.
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
18. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, version 4. Evanston, IL: Center on Outcomes Research and Education, Evanston Northwestern Healthcare and North-western University; November 1997.
19. Coleman RE. Clinically available evaluation of bone disease in breast cancer - validity and cost effectiveness. Can J Oncol. 1995;5(suppl 1):69-79.
20. Weinfurt K. Repeated measures analysis: ANOVA, MANOVA, and HLM. In: Grimm L, Yamold P, eds. Reading and Understanding More Multivariate Statistics. Washington, DC: American Psychological Association; 2000:317-361.
21. Stram DO, Lee JW. Variance components testing in the longitudinal mixed effects model. Biometrics. 1994;50:1171-1177.
22. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag; 2000.
23. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-655.
24. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988:412-414.
25. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15:141-155.
26. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol. 1998;16:1588-1593.
27. Ganz PA, Schag AC, Lee JJ, et al. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer. 1992;69:1729-1738.
28. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48:1507-1515.
29. Ingham J, Seidman A, Yao TJ, et al. An exploratory study of frequent pain measurement in a cancer clinical trial. Qual Life Res. 1996;5:503-507.